EDP
Evidence Grade E — Very limited evidence. 1 published studies. 0 registered clinical trials.
Crystagen is a synthetic tripeptide identified as a component of Thymalin, the registered Russian thymic extract. It is proposed to replicate some of Thymalin's immune-modulating effects as a defined synthetic molecule rather than a crude extract. No controlled human clinical trials meeting Western standards have been conducted.
Crystagen has no marketing authorisation as a standalone product from any major regulatory agency. A clinical study in elderly patients with impaired immunity reported improved immunological parameters when Crystagen was added to standard treatment, but this study's methodology has not undergone Western regulatory review.
As a defined synthetic component of the approved Russian extract Thymalin (#121), Crystagen represents an attempt to identify specific active peptides from the crude mixture. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Crystagen may modulate immune cell populations including T-cell subsets and macrophage cytokine secretion. These proposed effects are based on the compound's identification as a component of Thymalin and on in vitro immune cell studies.
Research suggests Crystagen has approximately 5-6 publications with both animal and human data, benefiting from its relationship to the broader Thymalin literature. Specific immunological endpoints were measured in a clinical study of elderly patients with impaired immunity. However, all data originate from the Khavinson group, the clinical study lacks sample size and statistical reporting details, and no independent replication exists. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
